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Abstract
Background: Major surgery predisposes to endothelial glycocalyx injury. Endothelial glycocalyx injury associates with
cardiac morbidity, including spontaneous myocardial infarction. However, the relation between endothelial glycocalyx
injury and the development of perioperative myocardial infarction remains unknown.
Methods: Fifteen perioperative myocardial infarction patients and 60 propensity-matched controls were investigated in
this prospective study. The diagnosis of perioperative myocardial infarction was based on repeated cardiac troponin
T measurements, electrocardiographs and recordings of ischaemic signs and symptoms. We measured endothelial
glycocalyx markers – soluble thrombomodulin, syndecan-1 and vascular adhesion protein 1 – and an inflammatory
marker, namely interleukin-6, preoperatively and 6 h and 24 h postoperatively. We calculated the areas under the
receiver operating characteristics curves (AUCs) to compare the performances of the different markers in predicting
perioperative myocardial infarction. The highest value of each marker was used in the analysis.
Results: The interleukin-6 concentrations of perioperative myocardial infarction patients were significantly higher
preoperatively and 6 and 24 h postoperatively (P¼ 0.002, P¼ 0.002 and P¼ 0.001, respectively). The AUCs (95% con-
fidence intervals) for the detection of perioperative myocardial infarction were 0.51 (0.34–0.69) for soluble thrombo-
modulin, 0.63 (0.47–0.79) for syndecan-1, 0.54 (0.37–0.70) for vascular adhesion protein 1 and 0.69 (0.54–0.85) for
interleukin-6.
Conclusions: Systemic inflammation, reflected by interleukin-6, associates with cardiac troponin T release and
perioperative myocardial infarction. Circulating interleukin-6 demonstrated some potential to predict perioperative
myocardial infarction, whereas endothelial glycocalyx markers did not.
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Major surgery causes sympathoadrenal activation and
systemic inflammation, exposing the organ system to
ischaemia-reperfusion (I/R) injury. In addition, exten-
sive perioperative fluid management may contribute to
endothelial injury. The vascular endothelium represents
the main organ affected by systemic inflammation, I/R
injury and hypervolemia, leading to endothelial activa-
tion and endothelial glycocalyx (EG) injury.1–5 After
early endothelial distress, circulating EG components
(syndecan-1) and endothelial cell integral membrane
proteins (soluble thrombomodulin [sTM] and vascular
adhesive protein [VAP-1]) are released into plasma and
have been suggested to be sensitive markers of endothe-
lial damage and potentially imminent organ injury.6
Pro-inflammatory cytokine IL-6 is central in acute-
phase reactions caused by infection or tissue trauma.7
The important role of EG injury has been estab-
lished in numerous critical illnesses, including sepsis
and acute kidney injury (AKI), and it is associated
with increased mortality.8–10 Furthermore, EG injury
associates with cardiovascular morbidity, including
acute coronary syndrome (ACS).11–13 However, no
data exist on the association of EG injury with periop-
erative myocardial infarction (PMI).
The objective of this study was to investigate the
relation of EG injury and systemic inflammation with
perioperative myocardial injury/infarction, evaluated
by serial measurements of EG markers and IL-6. We
hypothesized that acute inflammation and EG injury
are associated with perioperative cardiac troponin
T (cTnT) release and PMI.
Methods
Study design
This was a laboratory substudy of a prospective, obser-
vational single-centre study investigating the incidence
of major perioperative cardiac events in patients under-
going systematic perioperative ischaemia screening,
conducted at the Meilahti Hospital, Helsinki, Finland,
in 2014.14 Ethical approval for the study (no. 11/13/03/
02/2014) was provided by the Ethics Committee of the
Department of Surgery at Helsinki University Hospital,
Helsinki, Finland, on 30 January 2014. All patients or
their next of kin signed a written informed consent
before enrolment. In brief, we included 385 consecutive
patients, aged 50 years or older, undergoing non-cardiac
(vascular, thoracic or gastrointestinal) surgery between
3 April and 19 June 2014. Organ transplantations and
hepatic surgery were excluded. In this substudy, we
included all PMI patients with available baseline and
follow-up blood samples (n¼ 15), as well as four
propensity-matched controls for each PMI patient
(n¼ 60). The variables used for matching were age,
sex, main medical history, medications and intraopera-
tive data.
Patient management and data collection
The procedure for obtaining the patients’ medical his-
tory, demographics, medication, physiological and sur-
gical data has been explained in detail previously.14
A blood sample for cTnT and an electrocardiograph
(ECG) were obtained five times: preoperatively, 6 h
from the conclusion of the operation, and on the first,
second and third postoperative morning, or until dis-
charge. Together with cTnT, we took 5mL of EDTA
plasma for a future analysis of endothelial EG markers
and IL-6. Possible ischaemic signs and symptoms were
obtained from the patients’ charts and medical records
filled in daily by the treating clinical staff. Based on
repeated cTnT measurements, ECGs and clinical obser-
vations, a cardiologist (JV) blinded to the EG marker
and IL-6 analyses confirmed all PMI diagnoses. The
diagnosis of PMI was defined as a rise and/or a decline
in cTnT, with at least one value above the upper refer-
ence limit (14 ng/L), and either ischaemic ECG changes
or other ischaemic features present (symptoms of cardi-
ac ischaemia, cardiac imaging evidence of myocardial
infarction, autopsy findings of acute or healing myocar-
dial infarction), as recommended.15
Blood samples and enzyme-linked immunosorbent
assay analyses
Our focus was on perioperative EG injury, which is why
only blood samples taken preoperatively and 6 and 24h
after surgery were analysed. cTnT concentrations were
analysed immediately after sampling from a vein or an
arterial catheter. We used a high-sensitivity fifth-
generation troponin T assay (electrochemiluminescense
immunoassay [ECLIA]; Roche Diagnostics
International Ltd, Rotkreuz, Switzerland) for the anal-
yses. The limit of detection (LoD), analytical range,
10% coefficient of variation level and 99th percentile
cut-off point were 5 ng/L, 5–10,000ng/L, 13 ng/L and
14ng/L, respectively. Plasma samples were centrifuged
at 22 C at 3170 r/min for 10min within 3 h of sample
collection. The centrifuged samples were stored in
MekaminiTM tubes (Mekalasi Oy, Nurmij€ari, Finland)
at –80C until all samples were collected for analysis.
The biomarkers of EG injury (sTM, syndecan-1 and
VAP-1) and the activation of the inflammatory system
(IL-6) were analysed at the Minerva Foundation
Institute for Medical Research, Helsinki, Finland, with
commercially available immunoassays according to the
manufacturers’ recommendations: sTM (QuantikineTM
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ELISA, R&D Systems Europe, Ltd, Abingdon, UK),
LoD 0.0078pg/L, intra- and inter-assay coefficient of
variation (CV) 2.3%–3.6% and 5.7–8.0%); syndecan-1
(Human sCD138 [syndecan-1] ELISA Kit, Nordic
BioSite AB. T€aby, Sweden), LoD 0.0049ng/L, intra-
and inter-assay CV 6.2% and 10.2%, respectively;
VAP-1 (QuantikineTM ELISA, R&D Systems Europe,
Ltd, Abingdon, UK), LoD 0.000024ng/L, intra- and
inter-assay CV 1.5%–2.4% and 4.5%–4.8%, respective-
ly; IL-6 (QuantikineTM ELISA, R&D Systems Europe,
Ltd, Abingdon, UK), LoD <0.0007 pg/L, intra- and
inter-assay CV 1.6%–4.2% and 3.3%–6.4%, respective-
ly. In one patient, the preoperative IL-6 value was under
the LoD. All other endothelial and inflammatory
markers were above the LoD.
Outcomes
To explore the association of EG injury and systemic
inflammation, as reflected by IL-6, with cTnT release
and PMI.
Statistical analyses
The assumption of a clinically significant two-fold
increased level of laboratory parameters (sTM,
syndecan-1, VAP-1, IL-6) in PMI patients compared
with non-PMI patients and of a standard deviation
equal to the difference would require a sample size of
at least 10 patients and 40 controls (with a significance
level of 0.05 and a power of 80%). Based on these
assumptions, we considered a total sample size of 75
patients (15 PMI patients and 60 propensity-matched
non-PMI patients) to be adequate for comparisons
between the groups. To match controls with PMI
patients, we calculated a propensity score for each
patient based on demographic and medical data. The
variables included in the propensity matching are pre-
sented in supplemental digital content (S) Table 1. In
brief, the variables included age, sex, main medical his-
tory, medications and intraoperative data. Four
propensity-matched controls were selected for each
PMI patient.
We present continuous variables as medians with
interquartile ranges (IQRs) and dichotomous variables
as absolute numbers with percentages. The compari-
sons of continuous variables and frequencies were
made using the Mann-Whitney U-test and Fisher’s
exact test, respectively. We calculated the Hodges-
Lehmann estimator with 95% CIs to measure the
magnitude of differences between PMI patients’ and
non-PMI patients’ preoperative, 6 h and 24 h postoper-
ative values, as well as the highest values of EG
markers and IL-6. We calculated the areas under the
receiver operating characteristics curves (AUC) with
95% CIs. The highest plasma concentrations of EG
markers and IL-6 were used as test variables. We
defined an AUC of 0.5–0.75 as poor, 0.75–0.9 as
good and >0.9 as excellent, as suggested.16 A two-
sided P-value of <0.05 was considered significant.
Statistical analyses were performed with SPSS version
23 (SPSS; Chicago, IL, USA).
Results
With regard to PMI, a total of 75 patients (15 with
PMI and 60 matched controls) were included in the
present study (Figure 1). In order to assess the gener-
alizability of the current results, we compared the base-
line characteristics of the primary study patients with
all plasma samples taken to those with lacking plasma
samples. The results are presented in Tables S1 and S2.
With the exception of the differences in the numbers of
urgent/emergency operations, the use of vasopressor
support, the American Society of Anesthesiologists
class and perioperative cardiac risk,17 the patients
were comparable in terms of baseline characteristics.
PMI
The demographics, medical history and preoperative
clinical findings of the PMI patients and their
propensity-matched controls are summarized in
Table 1. The 90-day mortality of PMI patients was
20%, compared with the 8.3% among non-PMI patients.
Table 2 presents the median values of EG markers
and IL-6 in patients with and without PMI. The PMI
patients had higher IL-6 concentrations during the
whole perioperative 24 h follow-up, but the sTM,
syndecan-1 and VAP-1 concentrations were compara-
ble in patients with and without PMI at all time points.
The association of systemic inflammation and EG
injury with perioperative cTnT release
Figure 2 illustrates the kinetics of the EG markers and
IL-6 in patients with and without PMI. The IL-6 con-
centrations of PMI patients were significantly higher
across all time points – P¼ 0.002, P¼ 0.002 and
P¼ 0.001, respectively. However, the sTM, syndecan-
1 and VAP-1 concentrations did not differ between
PMI and non-PMI patients.
We tested the potential correlations between cTnT,
IL-6 and EG markers in PMI and non-PMI patients
with Spearman’s rho. The correlations are presented in
Tables S3A and S3B. The preoperative IL-6 concentra-
tion had a positive correlation with preoperative, 6 h
postoperative and 24 h postoperative cTnT in PMI
patients, P¼ 0.05. Furthermore, in PMI patients, the
24 h postoperative sTM correlated positively with
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preoperative, 6 h postoperative and 24 h postoperative
cTnT (P¼ 0.05). In non-PMI patients, the sTM and
cTnT concentrations correlated positively preopera-
tively (P< 0.001), 6 h postoperatively (P¼ 0.001) and
24 h postoperatively (P< 0.001).
The association of systemic inflammation and EG
injury with PMI
Figure 3 is a graphic representation of the performance
of the EG markers and IL-6 in predicting PMI. The
results of the analysis are summarized in Table 3. None
of the EG markers were predictive of PMI when the
highest values were analysed. IL-6 predicted PMI with
an AUC of 0.69 (95% CI 0.54–0.85), P¼ 0.02. The best
cut-off value for IL-6 was 0.238 pg/L, with a sensitivity
of 0.53, specificity of 0.85 and positive and negative
likelihood ratios of 3.56 (95% CI 1.65–7.65) and 0.55
(95% CI 0.32–0.95), respectively.
Discussion
In this prospective laboratory study, we demonstrated
that high IL-6 concentrations during the perioperative
period were associated with cTnT release and PMI.
Furthermore, a high perioperative IL-6 concentration
may be predictive of PMI, whereas EG markers (sTM,
syndecan-1 and VAP-1) were not.
The vascular endothelium is an active paracrine,
endocrine and autocrine organ that is crucial in regu-
lating vascular tone and maintaining vascular homeo-
stasis. Moreover, previous observations indicate that
endothelial dysfunction may represent a key early
step in the development of atherosclerosis and that it
is also involved in plaque progression and the occur-
rence of atherosclerotic complications.18,19 According
to current knowledge, endothelial dysfunction may
play a critical role in the development of ACS, as a
dysfunctional endothelium causes a pro-inflammatory
state that contributes to enhanced coronary plaque













Age 75 [65–86] 70 [62–76] 71 [64–77]
Gender (male) 9 (60) 39 (65) 48 (64)
Comorbidity
CAD 5 (33.3) 16 (26.7) 21 (28)
Heart failure 4 (26.7) 7 (11.7) 11 (14.7)
Baseline creatinine >177 mmol/L 2 (13.3) 2 (3.3) 4 (5.3)
ASO 9 (60) 18 (30) 27 (36)
Hypertension 8 (53.3) 39 (65.0) 47 (62.7)
Diabetes 2 (13.3) 19 (31.7) 21 (28)
COPD 6 (40) 8 (13.3) 14 (18.7)
Current malignancy 0 10 (16.7) 10 (13.3)
Prior
Acute MI 4 (26.7) 9 (15) 13 (17.3)
PCI/CABG 3 (20) 10 (16.7) 13 (17.3)
Stroke/TIA 4 (26.7) 16 (26.7) 20 (26.7)
ASA classification
II 0 6 (10) 6 (8)
III 9 (60) 34 (56.7) 43 (57.3)
IV–V 6 (40) 19 (31.7) 25 (33.3)
Perioperative cardiac risk score17 1.19 [0.66–3.73] 0.79 [0.54–2.04] 0.81 [0.61–2.55]
Urgent/emergency operation 11 (73.3) 37 (61.7) 48 (64)
Vasopressor load during the day of surgery (mg) 2.87 [0.48–6.76] 0.70 [0.01–1.51] 0.75 [0.11–2.50]
Nadir Hb during hospitalization (g/L) 95 [88–113] 103 [90–120] 102 [89–119]
PMI: perioperative myocardial infarction; IQR: interquartile range; CAD: coronary artery disease; ASO: atherosclerotic disease; COPD: chronic
obstructive pulmonary disease; MI: myocardial infarction; PCI: percutaneous coronary intervention; CABG: coronary artery bypass grafting; TIA,
transient ischemic attack; ASA: American Society of Anesthesiologists; Hb: haemoglobin concentration.
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vulnerability.20 It also has a decreased ability to pro-
duce nitric oxide, resulting in vasospasm and impaired
coronary arterial flow.20 Furthermore, endothelial dys-
function is characterized by a reduced anticoagulatory
potential of the endothelium, an increased endothelial
production of pro-coagulation mediators and an
increased vasoconstriction due to platelet-derived
mediators,11 resulting in a thrombogenic vascular
environment.
Several studies have demonstrated the occurrence of
EG injury in medical conditions characterized by
sympathoadrenal activation, systemic inflammation
and I/R injury.8,10,21,22 Ostrowski et al. investigated
patients with an acute ST segment elevation myocardi-
al infarction (STEMI), admitted for primary percuta-
neous coronary intervention (pPCI) and demonstrated
that these patients presented with high plasma concen-
trations of circulating sTM, syndecan-1, adrenalin and
noradrenalin. The authors showed that high circulating
sTM was associated with myocardial injury as defined
by high troponin I (TnI) release, and a similar tendency
was seen in the current study (Tables S3A and S3B).
Figure 1. Study flowchart.
PMI: perioperative myocardial infarction.
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Moreover, high syndecan-1 concentrations were asso-
ciated with short- and long-term mortality and heart
failure.10 Sustained EG injury associates with the sever-
ity of post-cardiac arrest syndrome (PCAS), as was
recently demonstrated by Bro-Jeppesen et al.22 The
authors showed that baseline IL-6 concentrations
were associated with EG activation and endothelial
cell injury in patients with severe myocardial
damage.22 However, to the best of our knowledge, no
previous study exists concerning the association of
endothelial injury with PMI.
The markers used to demonstrate EG activation and
injury vary extensively between the studies. The differ-
ent markers detected in circulating plasma represent
the different phases of the endothelial activation
and injury.
Firstly, we investigated thrombomodulin (TM), an
integral membrane protein expressed on the surface of
endothelial cells. It has a critical role as a cofactor in
the protein C pathway that is important in regulating
coagulation and inflammation. sTM circulates in
plasma and is found in increased concentrations in con-
nection with various diseases, such as cardiovascular
disease and diabetes, and in ischaemic or inflammatory
endothelial damage.23 We found that the sTM concen-
trations correlated with cTnT release, especially in
patients with no PMI. However, circulating sTM was
not predictive of PMI.
Secondly, we measured syndecan-1, an endothelial
cell transmembrane protein, which exists in the form of
proteoglycans. Previous animal studies suggest that the
shedding of EG is associated with a significant increase
in circulating syndecan-1,24,25 and this also appears to
occur in humans during I/R injury.9 In accordance with
these findings, we observed a rise in syndecan-1 con-
centrations when preoperative and 6 h postoperative
values were compared. Like sTM, syndecan-1 was not
predictive of PMI.
Thirdly, we studied VAP-1, which belongs to a
family of semicarbamizide-sensitive amine oxidases
(SSAOs) and is expressed in endothelial cells. VAP-1
plays an important role in controlling neutrophil adhe-
sion to the endothelium and neutrophil extravasation
from blood to tissues. Increased VAP-1 activity has
been observed in critically ill patients with septic
shock,26 and elevated concentrations have also been
described in obese and diabetic persons.27 According
to our findings, VAP-1 did not associate with










sTM 3.95 [3.13–7.02] 4.17 [3.47–4.74] 0.87 –60.0 (–1014.0, 751.0)
Syndecan-1 0.06 [0.05–0.09] 0.06 [0.04–0.08] 0.17 –9.0 (–23.0, 5.5)
VAP-1 0.36 [0.30–0.51] 0.36 [0.30–0.47] 0.66 –13.5 (–86.0, 56.0)
IL-6 0.03 [0.01–0.09] 0.007 [0.003–0.03] 0.008 –13.3 (–27.3, –3.6)
6 h postoperative
sTM 3.50 [2.94–5.25] 4.00 [3.39–4.69] 0.47 200.0 (–501.0, 846.0)
Syndecan-1 0.10 [0.06–0.12] 0.07 [0.04–0.12] 0.15 –13.4 (–38.3, 7.1)
VAP-1 0.32 [0.25–0.38] 0.33 [0.26–0.42] 0.57 18.0 (–46.0, 78.0)
IL-6 0.21 [0.05–0.29] 0.07 [0.03–0.12] 0.013 –72.1 (–182.3, –12.2)
24 h postoperative
sTM 4.05 [3.71–5.32] 4.30 [3.65–5.07] 0.94 44.5 (–661.0, 645.0)
Syndecan-1 0.07 [0.05–0.1] 0.07 [0.05–0.09] 0.44 –7.0 (–24.4, 11.2)
VAP-1 0.30 [0.26–0.40] 0.33 [0.26–0.42] 0.53 16.5 (–35.0, 74.0)
IL-6 0.21 [0.10–0.32] 0.07 [0.02–0.15] 0.006 –93.2 (–199.2, –23.1)
Highest
sTM 4.19 [3.72–7.02] 4.37 [3.65–5.34] 0.87 –76.5 (–920.0, 646.0)
Syndecan-1 0.11 [0.06–0.14] 0.07 [0.06–0.11] 0.12 –19.1 (–48.9, 4.8)
VAP-1 0.38 [0.30–0.51] 0.37 [0.30–0.47] 0.67 –15.5 (–90.0, 57)
IL-6 0.24 [0.10–0.35] 0.10 [0.04–0.19] 0.022 –93.1 (–213.0, –12.0)
IL-6: interleukin-6 (pg/L); EG: endothelial glycocalyx; PMI: perioperative myocardial infarction; HL: Hodges-Lehman estimator; IQR: interquartile range;
CI: confidence interval; sTM: soluble thrombomodulin (pg/L); syndecan-1 (ng/L); VAP-1: vascular adhesion protein 1 (ng/L).
6 Annals of Clinical Biochemistry 0(0)
perioperative cTnT release or myocardial infarction. In
addition to EG markers, IL-6 was measured as a pro-
inflammatory cytokine produced mainly by macro-
phages and monocytes at an inflammatory site. IL-6
is a main stimulator in acute-phase reactions following
an infection or tissue trauma but also plays an impor-
tant role in the development of chronic inflammation.7
According to the current findings, a perioperative rise
in IL-6 is associated with PMI and might be predictive
of the complication.
The superiority of any endothelial marker in dem-
onstrating endothelial injury in the clinical setting and
in predicting the patients’ outcome has not been dem-
onstrated. In a perioperative setting, Rehm et al.
Figure 2. The kinetics of endothelial glycocalyx markers and interleukin-6 in PMI and non-PMI patients. Non-transformed values are
presented on a logarithmic scale. Bars represent medians with interquartile ranges (IQRs). T-bars represent values 1.5 times greater
than the IQR.
PMI: perioperative myocardial infarction; sTM: soluble thrombomodulin; VAP-1: vascular adhesion protein 1; IL-6: interleukin-6.
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Table 3. The highest values of EG markers (sTM, syndecan-1 and VAP-1) and IL-6 in predicting PMI.
AUC (95% CI)
Cut-off
value Sensitivity Specificity LRþ (95%CI) LR– (95% CI)
Youden
index PPV% NPV%
sTM 0.51 (0.34–0.69) 6.83 0.27 0.95 5.33 (1.33–21.33) 0.77 (0.57–1.05) 0.22 57.1 83.8
Syndecan-1 0.63 (0.47–0.79) 0.11 0.53 0.80 2.67 (1.33–5.33) 0.58 (0.33–1.02) 0.33 40.0 87.3
VAP-1 0.54 (0.37–0.70) 0.43 0.47 0.70 1.56 (0.8–3.02) 0.76 (0.46–1.26) 0.17 28.0 84.0
IL-6 0.69 (0.54–0.85) 0.24 0.53 0.85 3.56 (1.65–7.65) 0.55 (0.32–0.95) 0.38 47.1 87.9
Note: Sensitivity, specificity, positive and negative predictive values were calculated using optimal cut-off values determined with Youden index.
EG: endothelial glycocalyx; sTM: soluble thrombomodulin (pg/L); syndecan-1 (ng/L); VAP-1: vascular adhesion protein 1 (ng/L); IL-6: interleukin-6 (pg/L);
PMI: perioperative myocardial infarction; AUC: area under receiver operating characteristics curve; CI: confidence interval; LRþ: positive likelihood
ratio; LR–: negative likelihood ratio; PPV: positive predictive value; NPV: negative predictive value.
Figure 3. The highest values of the EG markers and IL-6 in predicting PMI. A: sTM, B: IL-6, C: syndecan-1, D: VAP-1.
AUC: area under the receiver operating characteristics curve; CI: confidence interval.
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demonstrated that plasma syndecan-1 and heparan sul-
phate concentrations rose in patients undergoing pro-
cedures predisposing them to either global or regional
ischaemia followed by reperfusion, whereas intercellu-
lar adhesion molecule-1 (ICAM-1) and vascular cell
adhesion molecule-1 (VCAM-1) concentrations
remained unchanged.9 This finding led the authors to
the conclusion that the circulating components of EG
may be more sensitive markers of EG injury than inte-
gral membrane proteins. Furthermore, Rehm et al.
observed a high interindividual variation in EG shed-
ding, which is in broad agreement with our results. The
differences in surgical procedures, perioperative man-
agement and the patients’ medical condition are a plau-
sible explanation for the variation.
Despite the great emphasis on perioperative care
during the past years, PMI remains a severe complica-
tion, with an in-hospital mortality of 12%–40%.28–31
Perioperative hemodynamic instability, leading to
oxygen demand/supply disparity, as well as blood
flow stagnation and thrombus formation are regarded
as major factors in the development of PMI.32
Therefore, most trials have been targeted towards pre-
venting these adverse factors. However, despite numer-
ous large-scale clinical studies,33–35 efficient and safe
methods to prevent PMI are still lacking, and it is
likely that we remain unaware of the exact pathophys-
iological mechanisms of PMI. Considering the physio-
logical disturbances – with impaired vasodilatation,
enhanced plaque vulnerability and pro-thrombotic
state in particular – caused by a dysfunctional endothe-
lium, endothelial injury seems a logical contributor in
the development of PMI. Furthermore, several studies
have demonstrated an association between the presence
of coronary endothelial dysfunction and ischaemic
symptoms or imaging findings in individuals without
clinically significant coronary artery disease.36–39 This
might explain the fact that perioperative cardiac com-
plications are sometimes hard to predict and may occur
in patients with relatively clean coronary arteries.40
To the best of our knowledge, this was the first study
to suggest that EG injury may play a role in the path-
ophysiology of PMI, and this finding opens the door
for possible future therapeutic trials. An interesting
report published by Manchurov et al. demonstrated
that remote ischaemic preconditioning (RIPC) before
pPCI clearly improved the endothelial function in
patients with an acute myocardial infarction.41
Whether similar effects can be achieved in surgical
patients and whether this is beneficial in preventing
perioperative cardiac complications and improving
perioperative outcome could be a subject of future clin-
ical trials. In order to conduct these trials, though,
larger observational studies on the association between
EG injury and perioperative cardiac complications
are needed.
The current study has some important limitations.
Firstly, because of the missing blood samples, we were
not able to include all consecutive patients of the pri-
mary study and, unfortunately, had to exclude 12 PMI
patients. The current results should be interpreted
taking this into consideration. However, as presented
in Tables S1 and S2, patients with and without all
blood samples available were comparable regarding
their baseline characteristics. Additionally, we matched
controls for the PMI patients using a propensity score
and increased the statistical power by including four
controls for each PMI patient. Secondly, this was an
observational study, not allowing an evaluation of the
causal relationship. Finally, the assessment of diagnos-
tic ability (using positive likelihood ratios) was based
on cut-off values derived from the same study because
previous values for PMI patients did not exist in the
literature. Despite the small sample size, there was a
fairly strong correlation between cTnT, IL-6 and EG
markers in 15 PMI patients. Thus, our findings should
be considered as first hypothesis-generating prelimi-
nary evidence regarding the potential association
between EG injury and PMI.
Conclusion
Systemic inflammation, reflected by IL-6, associates
with cTnT release and PMI. Furthermore, IL-6 dem-
onstrated some potential to predict PMI, whereas EG
markers did not. These findings should be considered
preliminary and need to be confirmed or refuted in
larger future studies.
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